Cargando…

The clinical utility of polygenic risk scores for chronic lymphocytic leukemia

Detalles Bibliográficos
Autores principales:	Sud, Amit, Law, Philip J., Houlston, Richard S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632671/ https://www.ncbi.nlm.nih.gov/pubmed/34564698 http://dx.doi.org/10.1038/s41375-021-01429-5

Ejemplares similares

Will polygenic risk scores for cancer ever be clinically useful?
por: Sud, Amit, et al.
Publicado: (2021)

Types of second primary cancers influence survival in chronic lymphocytic and hairy cell leukemia patients
por: Zheng, Guoqiao, et al.
Publicado: (2019)

Polygenic risk scores to stratify cancer screening should predict mortality not incidence
por: Vickers, Andrew J., et al.
Publicado: (2022)

Genetic predisposition to chronic lymphocytic leukemia
por: Law, Philip J., et al.
Publicado: (2019)

Realistic expectations are key to realising the benefits of polygenic scores
por: Sud, Amit, et al.
Publicado: (2023)

Genetic risk scores may compound rather than solve the issue of prostate cancer overdiagnosis
por: Horton, Rachel H., et al.
Publicado: (2022)

Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African Americans
por: Kleinstern, Geffen, et al.
Publicado: (2021)

Risk Stratification and Clinical Utility of Polygenic Risk Scores in Ophthalmology
por: Qassim, Ayub, et al.
Publicado: (2021)

Clinical utility of polygenic scores for cardiometabolic disease in Arabs
por: Shim, Injeong, et al.
Publicado: (2023)

On the utilization of polygenic risk scores for therapeutic targeting
por: Gibson, Greg
Publicado: (2019)

Clinical utility of polygenic risk scores: a critical 2023 appraisal
por: Koch, Sebastian, et al.
Publicado: (2023)

Post‐GWAS Polygenic Risk Score: Utility and Challenges
por: Nguyen, Tuan V, et al.
Publicado: (2020)

Fatal Powassan virus encephalitis in patients with chronic lymphocytic leukemia
por: Johnson, Isla M., et al.
Publicado: (2022)

Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia
por: Muhowski, Elizabeth M., et al.
Publicado: (2022)

Integrating genome-wide polygenic risk scores and non-genetic risk to predict colorectal cancer diagnosis using UK Biobank data: population based cohort study
por: Briggs, Sarah E W, et al.
Publicado: (2022)

Patient and provider perspectives on polygenic risk scores: implications for clinical reporting and utilization
por: Lewis, Anna C. F., et al.
Publicado: (2022)

Unusual involvement of cervix and vulva in a case of chronic lymphocytic leukemia
por: Udupa, Karthik, et al.
Publicado: (2012)

Analysis of criteria for treatment initiation in patients with progressive chronic lymphocytic leukemia
por: Mozas, Pablo, et al.
Publicado: (2018)

Current Developments of Clinical Sequencing and the Clinical Utility of Polygenic Risk Scores in Inflammatory Diseases
por: Hübenthal, Matthias, et al.
Publicado: (2021)

Clinical and Cytogenetic Characterization, and Outcome of Chronic Lymphocytic Leukemia Patients in a Single Tertiary Center in Saudi Arabia
por: Al Mugairi, Areej, et al.
Publicado: (2023)

Second cancer risk following Hodgkin lymphoma
por: Sud, Amit, et al.
Publicado: (2017)

The clinical utility of polygenic risk scores in genomic medicine practices: a systematic review
por: Kumuthini, Judit, et al.
Publicado: (2022)

Identification of new putative driver mutations and predictors of disease evolution in chronic lymphocytic leukemia
por: Mosquera Orgueira, Adrián, et al.
Publicado: (2019)

Covid-19 infection in therapy-naive patients with B-cell chronic lymphocytic leukemia
por: Paneesha, S., et al.
Publicado: (2020)

Hepatitis B Virus Reactivation in a Chronic Lymphocytic Leukemia Patient Treated with Ibrutinib
por: Choi, Jung Hye, et al.
Publicado: (2023)

Improving the Utility of Polygenic Risk Scores as a Biomarker for Alzheimer’s Disease
por: Vlachakis, Dimitrios, et al.
Publicado: (2021)

Polygenic risk scores in the clinic: Translating risk into action
por: Lewis, Anna C.F., et al.
Publicado: (2021)

Evaluating Genomic Polygenic Risk Scores for Childhood Acute Lymphoblastic Leukemia in Latinos
por: Jeon, Soyoung, et al.
Publicado: (2023)

Evaluating genomic polygenic risk scores for childhood acute lymphoblastic leukemia in Latinos
por: Jeon, Soyoung, et al.
Publicado: (2023)

Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy
por: Popovic, Relja, et al.
Publicado: (2021)

Potential use of clinical polygenic risk scores in psychiatry – ethical implications and communicating high polygenic risk
por: Palk, A. C., et al.
Publicado: (2019)

Risk of developing chronic lymphocytic leukemia is influenced by HLA-A class I variation
por: Di Bernardo, Maria Chiara, et al.
Publicado: (2012)

MYD88 mutations predict unfavorable prognosis in Chronic Lymphocytic Leukemia patients with mutated IGHV gene
por: Qin, Shu-Chao, et al.
Publicado: (2017)

Validation and functional characterization of GWAS-identified variants for chronic lymphocytic leukemia: a CRuCIAL study
por: García-Martín, Paloma, et al.
Publicado: (2022)

ATM germline variants in a young adult with chronic lymphocytic leukemia: 8 years of genomic evolution
por: Royo, Romina, et al.
Publicado: (2022)

Genome-wide homozygosity signature and risk of Hodgkin lymphoma
por: Sud, Amit, et al.
Publicado: (2015)

Polygenic transcriptome risk scores (PTRS) can improve portability of polygenic risk scores across ancestries
por: Liang, Yanyu, et al.
Publicado: (2022)

Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index
por: Wang, Yucai, et al.
Publicado: (2021)

Targeted Treatment of Chronic Lymphocytic Leukemia: Clinical Utility of Acalabrutinib
por: Vitale, Candida, et al.
Publicado: (2021)

Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort
por: Miao, Yi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ibqkv7aheuoo51t9kghsbapgrn